NEW YORK AND LONDON
Celsus Therapeutics (OTCQB: CLSXY), an emerging growth, development-stage biopharmaceutical company, announced that the Company MRX-6 treatment for eczema has been selected as one of the “Top 10 Autoimmune/Anti-Inflammatory Disease Projects to Watch” by Windhover Information, of Elsevier Business Intelligence, a global leader in the field of healthcare industry information.
